Dr. Li Xu 徐立
Chief Physician
Department of Hepatobiliary and Pancreatic Surgery, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive and minimally invasive surgical treatment of liver cancer, with a focus on systemic drug therapy and related clinical research.
Dr. Xu is a Chief Physician and PhD supervisor with over 20 years of experience in liver cancer diagnosis and treatment. Dr. Xu has treated over 10,000 patients and leads national research projects on patient selection, efficacy prediction, and biomarkers. Research findings have been published in international journals. Honors include the First Prize of Guangdong Provincial Science and Technology Progress Award.
Professional roles
- Member, Liver Cancer Quality Control Expert Committee, National Cancer Center
- Member, Liver Cancer Professional Committee, China Anti-Cancer Association
- Member, Liver Cancer Group, Hepatology Branch, Chinese Medical Association
- Vice Chair, Liver Cancer Branch, Guangdong Medical Association
Name order: in Chinese the family name comes first (Xu Li). Papers usually list the name as Li Xu or Xu L.
Selected publications
149 papers on PubMed matched by name and affiliation; 16 as first or senior author since 2016. Most recent first- or senior-author papers:
- Pharmacol Res, 2026 (senior author): A miR-221-3p-CDKN1B-CDK4/β-catenin axis couples tumor progression with response to CDK4/6 inhibition in intrahepatic cholangiocarcinoma. PubMed 43020401
- Int J Surg, 2026 (senior author): Hepatic arterial infusion chemotherapy plus sintilimab as conversion therapy for locally advanced hepatocellular carcinoma: a single-center phase II trial. PubMed 41537370
- JHEP Rep, 2026 (senior author): Pathological response ≥90% predicts survival in HCC treated with neoadjuvant loco-regional therapies: A retrospective cohort study. PubMed 41674893
- BMC Infect Dis, 2025 (senior author): Severe Rhodococcus equi pneumonia following hepatic arterial infusion chemotherapy combined with sintilimab and lenvatinib in hepatocellular carcinoma: a case report. PubMed 41353530
- J Hepatocell Carcinoma, 2025 (senior author): Hyper-Relapse Disease is a Special Pattern of Relapse of Hepatocellular Carcinoma After Curative Hepatectomy: A Retrospective Cohort Study. PubMed 40636774
- Mol Immunol, 2025 (first author): Dock2 deficiency reveals abnormal activation and differentiation of T cells under the physiological condition. PubMed 40101338
- Int J Surg, 2024 (senior author): Change of indocyanine green clearance ability and liver function after transcatheter intra-arterial therapies and its impact on outcomes of resectable hepatocellular carcinoma: a retrospective cohort study. PubMed 38363991
- BMC Med, 2024 (first author): Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial. PubMed 38650037
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion